Natco Pharma updates on Risdiplam launch in India, Delhi High Court denies Roche's injunction plea, pricing set at ₹15,900.

The Supreme Court will review the Rs 50 lakh cap on the central government's aid for treating rare diseases like SMA. The ...

Supreme Court examines pleas challenging 50 lakh cap on Centre's assistance for treating rare diseases like SMA.

Natco Pharma on Tuesday shared a legal update on the legal proceedings on the Risdiplam compound (used for treating spinal ...

Natco Pharma on April 8 said that the launch of its generic version of Roche Pharma's patented drug, Risdiplam, is contingent upon the successful outcome in a patent infringement case.

FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration ...

The Supreme Court on Friday asked the Centre and the manufacturer of the drug Risdiplam, which is used for the treatment of ...

It was submitted that why can't the Indian government negotiate with Roche to make the medicine for the rare disorder ...

The Supreme Court has sought responses from the Centre and pharmaceutical giant Roche on why their SMA treatment drug, ...

The Supreme Court on Tuesday decided to examine pleas challenging the Rs 50 lakh cap on Centre's assistance for treating ...

Natco Pharma plans to launch generic Risdiplam pending Delhi High Court decision, offering discounts to patients.